HELLP syndrome
ICD-10 O14.2 · ICD-11 JA24.2

HELLP Syndrome: When Convulsions Recur After First-Line Treatment Has Not Achieved Recovery Targets

HELLP syndrome requires prompt, structured management from the outset. In some patients, despite completing first-line therapy, platelet and liver enzyme recovery targets are not met and convulsions recur. This protocol addresses that specific clinical situation.

First-line treatment & escalation trigger

Initial management includes magnesium sulfate for seizure prevention and treatment, antihypertensive therapy (labetalol, hydralazine, or nifedipine) for acute severe-range blood pressure, delivery after maternal stabilisation, and corticosteroids when indicated. This protocol is reached when, within 7 days after delivery, the platelet count has not shown a rising trend above 100,000 ×109/L and liver enzyme values have not shown a consistent decreasing trend — and convulsions recur in this setting.

Next-step approach (partial overview)

When convulsions recur in this context, the protocol calls for a further intravenous administration of magnesium sulfate as the immediate intervention. The complete structured regimen specifies the precise parameters and any additional management steps.

Full dosing, sequencing, and decision criteria are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

It has been proposed that when convulsions recur, a further 2–4 grams of magnesium sulfate could be administered IV over 5 minutes.

DOI: 10.1097/AOG.0000000000003891

View source ↗